The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression
Open Access
- 29 November 2017
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 144 (2) , 269-283
Abstract
Background The nuclear factor-kappa B (NF-κB) signalling pathway is a regulator of immune response and inflammation that has been implicated in the carcinogenic process. We examined differentially expressed genes in this pathway and miRNAs to determine associations with colorectal cancer (CRC). Methods We used data from 217 CRC cases to evaluate differences in NF-κB signalling pathway gene expression between paired carcinoma and normal mucosa and identify miRNAs that are associated with these genes. Gene expression data from RNA-Seq and miRNA expression data from Agilent Human miRNA Microarray V19.0 were analysed. We evaluated genes most strongly associated and differentially expressed (fold change (FC) of > 1.5 or < 0.67) that were statistically significant after adjustment for multiple comparisons. Results Of the 92 genes evaluated, 22 were significantly downregulated and nine genes were significantly upregulated in all tumours. Two additional genes (CD14 and CSNK2A1) were dysregulated in MSS tumours and two genes (CARD11 and VCAM1) were downregulated and six genes were upregulated (LYN, TICAM2, ICAM1, IL1B, CCL4 and PTGS2) in MSI tumours. Sixteen of the 21 dysregulated genes were associated with 40 miRNAs. There were 76 miRNA:mRNA associations of which 38 had seed-region matches. Genes were associated with multiple miRNAs, with TNFSRF11A (RANK) being associated with 15 miRNAs. Likewise several miRNAs were associated with multiple genes (miR-150-5p with eight genes, miR-195-5p with four genes, miR-203a with five genes, miR-20b-5p with four genes, miR-650 with six genes and miR-92a-3p with five genes). Conclusions Focusing on the genes and their associated miRNAs within the entire signalling pathway provides a comprehensive understanding of this complex pathway as it relates to CRC and offers insight into potential therapeutic agents.Keywords
Funding Information
- National Cancer Institute (CA163683)
This publication has 41 references indexed in Scilit:
- MicroRNA-17~92 inhibits colorectal cancer progression by targeting angiogenesisCancer Letters, 2016
- RANKL/RANK control Brca1 mutation-driven mammary tumorsCell Research, 2016
- Expression Profiles of miRNA Subsets Distinguish Human Colorectal Carcinoma and Normal Colonic MucosaClinical and Translational Gastroenterology, 2016
- MiR-26b inhibits melanoma cell proliferation and enhances apoptosis by suppressing TRAF5-mediated MAPK activationBiochemical and Biophysical Research Communications, 2016
- Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancerOncogene, 2016
- MicroRNA profiles in colorectal carcinomas, adenomas and normal colonic mucosa: variations in miRNA expression and disease progressionCarcinogenesis, 2016
- The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinomaInternational Journal of Oncology, 2013
- MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiationNature Immunology, 2010
- Energy Balance and Rectal Cancer: An Evaluation of Energy Intake, Energy Expenditure, and Body Mass IndexNutrition and Cancer, 2003
- Energy balance and colon cancer--beyond physical activity.1997